| Business Summary | | InMedica
Development
Corporation
has
been
engaged
in
the
operation
of
the
business
of
MicroCor,
Inc.,
a
wholly
owned
subsidiary.
MicroCor
has
engaged
in
the
development
or
sale
of
certain
medical
technology
products.
However,
royalty
income
received
by
MicroCor
from
the
development
and
sale
of
technology
has
terminated.
During
fiscal
2000,
the
Company's
activities
focused
on
searching
for
additional
funding. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | InMedica,
through
its
wholly-owned
subsidiary,
MicroCor,
Inc.,
engages
in
research
and
development
of
an
experimental
device
to
measure
hematocrit
non-invasively.
For
the
three
months
ended
3/31/01,
revenues
totaled
$640,
up
from
$0.
Net
loss
applicable
to
Common
rose
7%
to
$77
thousand.
Revenues
reflect
recognition
of
royalty
income.
Higher
loss
reflects
higher
cost
from
operations
and
increased
interest
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Larry Clark, 78 Chairman | $12K | Ralph Henson, 55 Pres,
CEO, Director | 37K | Richard Bruggeman, 44 CFO,
Sec., Treasurer | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|